PDCD1 and cancer: Anti-ICOS agonists were already tested in mice studies and in clinical trials for cancer immunotherapy, and show promising results when used in combination with other checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 antibodies (85, 92, 93).